$CLX

Meet the 5.1%-Yielding Stock That Just Increased Its Dividend for the 49th Consecutive Year. Here's Why It's a Buy in August.

Clorox (CLX) completed its April 1 acquisition of Gojo Industries, adding Purell, which now drives more than half of net sales. For fiscal 2027, Clorox guides net sales up 13% to 14% and adjusted EPS of $5.70 to $6.00. It also raised its quarterly dividend to $1.25 and expects FCF at 11% to 13% of net sales.

Original reporting
Published Aug 5, 2026, 9:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Meet the 5.1%-Yielding Stock That Just Increased Its Dividend for the 49th Consecutive Year. Here's Why It's a Buy in August. — source image
Decision brief

The 30-second read

$CLXNeutralLow
01

Why it matters

The article’s core trading inputs are fiscal 2027 guidance (net sales, EPS, and FCF margin) and a small dividend increase, presented as evidence that the dividend remains affordable while the Purell segment drives growth.

02

Market read

For traders, the actionable element is the forward guidance and dividend update, but the piece is primarily a long-term buy argument rather than a new catalyst.

03

What to watch

ERP overhaul cost overruns ($580 million) and the widening range of outcomes could increase uncertainty around free cash flow durability, despite the stated FCF margin guidance.

Relevance 4/10Novelty 4/10Timing: August positioning, citing Aug. 3 prepared remarks and July 31 dividend increase

Background

Clorox completed the Gojo Industries acquisition on April 1, adding Purell, and is transitioning from ERP stabilization to optimization after a costly cyberattack and implementation delays.

Company-level read

Ticker impact

$CLXNeutralMedium confidence
Context

Clorox guides fiscal 2027 net sales up 13% to 14% with Gojo acquisition contributing 9.5%, and expects EPS $5.70 to $6.00.

Expected impact

Likely modest upside bias for dividend/value traders, but near-term reaction depends on how investors weigh guidance versus ongoing consumer-demand pressure.

Evidence & confidence

It provides specific forward guidance and dividend increase details, but it is a promotional buy thesis rather than a fresh earnings print or new regulatory/M&A disclosure within the article.

Market effects

Highlights how hygiene/consumer staples names may use acquisitions and ERP-driven efficiency to offset demand softness.

No specific regional demand or policy impacts discussed.

No explicit global macro or international regulatory drivers mentioned.

Counterpoint

The dividend yield argument may be a value trap if consumer value-seeking and category growth below historical levels persist beyond fiscal 2027.

Key entities

  • Clorox

    Subject of the article, with fiscal 2027 guidance, ERP/efficiency narrative, and a 49-year dividend increase streak.

  • Gojo Industries

    Acquisition completed April 1, with Purell now driving more than half of Clorox net sales and contributing 9.5% to the net sales forecast.

Related articles

$CLXMedAI 8/10

How GOJO Could Shape Clorox's Fiscal 2027 Growth and Margin Outlook

Clorox (CLX) expects fiscal 2027 net sales to rise 13-14%, with GOJO contributing 9.5 points. Q1 sales projected at 31-32%, including 15 points from GOJO. Adjusted earnings forecasted at $5.70-$6.00 per share, up 3-8%. Gross margin expected at 42%, with pressure from GOJO inventory costs and inflation. Integration costs and inflation pose near-term challenges.

$CLXMedAI 8/10

Is Clorox Stock Worth Buying as GOJO Growth Meets Margin Pressure?

Clorox (CLX) reports Q4 net sales of $1.95B, up 2% YoY, with GOJO contributing 10 percentage points. Fiscal 2027 sales expected to rise 13-14%, with adjusted EPS at $5.70-$6.00. Gross margins declined due to inflation and higher costs. Organic sales growth is muted, with ERP comparisons aiding growth. CLX trades at 17.9X forward earnings, below its sub-industry multiple.

$CLXMed

Are Wall Street Analysts Predicting Clorox Stock Will Climb or Sink?

The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.

$CLXMedAI 8/10

Clorox (CLX) Q4 2026 Earnings Call Transcript

Clorox (CLX) reported Q4 FY2026 net sales of $1.95B, down 2% (GOJO added about 10 points). Organic sales fell 13% and adjusted EPS was $1.66, down 42%. Gross margin was 41.3%. For FY2027, it guided organic sales growth of 3.5% to 4.5% and adjusted EPS of $5.70 to $6.00, citing inflation headwinds of $200M+.

$CLXMed

The Clorox Company Q4 2026 Earnings Call Summary

Clorox held its Q4 2026 earnings call, citing value-seeking consumer behavior and inflation pressures. Management said most categories have recovered from a prior cyberattack, with Litter still lagging. It highlighted GOJO acquisition synergies, fiscal 2027 assumptions including Brent at $90/bbl, inflation over $200M, and free cash flow of 11% to 13% of sales.

$CLXMedAI 8/10

Clorox fiscal 2027 outlook: inflation and value shoppers weigh

Clorox forecast a difficult fiscal 2027, citing inflation and consumers shifting to value. The company expects net sales up 13% to 14% for fiscal 2027, with about 9.5 points from its April 2026 GOJO Industries acquisition. Adjusted EPS is projected at $5.70 to $6.00, GAAP diluted EPS $5.41 to $5.71. Q4 revenue fell 2% to $1.95B; adjusted EPS was $1.66.